StemCells Completes SCS Acquisition | GenomeWeb

NEW YORK (GenomeWeb News) – StemCells today announced that it has completed its acquisition of UK-based Stem Cell Sciences for 2.65 million shares of its common stock and $700,000 in cash.

Based on the Tuesday closing price of StemCells' stock ($1.67), the deal is valued at around $4.4 million, lower than the $4.8 million estimated when the deal was signed in early March. SCS' shareholders overwhelmingly approved the deal last week at an extraordinary general meeting.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.